Medical Industry Feature: Making a Difference for Patients with Secondary Hyperparathyroidism

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Making a Difference for Patients with sHPT

Program Information

Program Information

Making a Difference for Patients with sHPT

Nephrology experts discuss the changing dynamics of nephrology care and how it can affect their patients with secondary hyperparathyroidism (sHPT).

  • Overview

    With the ever-increasing pace and pressures faced by nephrology professionals both in the office and at the dialysis center, how can you keep up? John Russell, MD welcomes two community nephrologists, David Henner, DO from Pittsfield, Massachusetts, and Adbul Abdellatif, MD, FASN from Houston, Texas, to talk about just that. Together, they explore how nephrologists are dealing with the changing landscape of nephrology and how a drug called Parsabiv® is playing a role in the important work they do.

    This promotional, non-CME program is intended for US Health Care Professionals. David Henner, DO and Adbul Abdellatif, MD, FASN were paid a fee by Amgen for their participation in the program.


    Parsabiv® (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. 

    Limitations of Use:

    Parsabiv® has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with CKD who are not on hemodialysis and is not recommended for use in these populations.


    Contraindication: Parsabiv® is contraindicated in patients with known hypersensitivity to etelcalcetide or any of its excipients. Hypersensitivity reactions, including face edema and anaphylactic reaction, have occurred.

    Hypocalcemia: Parsabiv® lowers serum calcium and can lead to hypocalcemia, sometimes severe. Significant lowering of serum calcium can cause QT interval prolongation and ventricular arrhythmia. Patients with conditions that predispose to QT interval prolongation and ventricular arrhythmia may be at increased risk for QT interval prolongation and ventricular arrhythmias if they develop hypocalcemia due to Parsabiv®. Closely monitor corrected serum calcium and QT interval in patients at risk on Parsabiv®.

    Significant reductions in corrected serum calcium may lower the threshold for seizures. Patients with a history of seizure disorder may be at increased risk for seizures if they develop hypocalcemia due to Parsabiv®. Monitor corrected serum calcium in patients with seizure disorders on Parsabiv®.

    Concurrent administration of Parsabiv® with another oral calcimimetic could result in severe, life-threatening hypocalcemia. Patients switching from cinacalcet to Parsabiv® should discontinue cinacalcet for at least 7 days prior to initiating Parsabiv®. Closely monitor corrected serum calcium in patients receiving Parsabiv® and concomitant therapies known to lower serum calcium.

    Measure corrected serum calcium prior to initiation of Parsabiv®. Do not initiate in patients if the corrected serum calcium is less than the lower limit of normal. Monitor corrected serum calcium within 1 week after initiation or dose adjustment and every 4 weeks during treatment with Parsabiv®. Measure PTH 4 weeks after initiation or dose adjustment of Parsabiv®. Once the maintenance dose has been established, measure PTH per clinical practice.

    Worsening Heart Failure: In Parsabiv® clinical studies, cases of hypotension, congestive heart failure, and decreased myocardial performance have been reported. Closely monitor patients treated with Parsabiv® for worsening signs and symptoms of heart failure.

    Upper Gastrointestinal Bleeding: In clinical studies, 2 patients treated with Parsabiv® in 1253 patient years of exposure had upper gastrointestinal (GI) bleeding at the time of death. The exact cause of GI bleeding in these patients is unknown and there were too few cases to determine whether these cases were related to Parsabiv®.

    Patients with risk factors for upper GI bleeding, such as known gastritis, esophagitis, ulcers or severe vomiting, may be at increased risk for GI bleeding with Parsabiv®. Monitor patients for worsening of common Parsabiv® GI adverse reactions and for signs and symptoms of GI bleeding and ulcerations during Parsabiv® therapy.

    Adynamic Bone: Adynamic bone may develop if PTH levels are chronically suppressed.

    Adverse Reactions: In clinical trials of patients with secondary HPT comparing Parsabiv® to placebo, the most common adverse reactions were blood calcium decreased (64% vs. 10%), muscle spasms (12% vs. 7%), diarrhea (11% vs. 9%), nausea (11% vs. 6%), vomiting (9% vs. 5%), headache (8% vs. 6%), hypocalcemia (7% vs. 0.2%), and paresthesia (6% vs. 1%).

    Please click here to see accompanying Parsabiv® full prescribing information.

    Please click here here to see accompanying Sensipar® full prescribing information.

    Visit and for more information.


    1. CenterWatch. 2019 FDA Approved Drugs. Accessed August 16, 2019.
    2. US-DOPPS Practice Monitor, April 2018. Accessed November 9, 2018.
    3. Parsabiv® (etelcalcetide) prescribing information, Amgen.
Programs 4/10/21